Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Lord Abbett & CO. LLC

Lord Abbett & CO. LLC lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 64,081 shares of the biopharmaceutical company’s stock after selling 22,151 shares during the period. Lord Abbett & CO. LLC owned about 0.06% of Regeneron Pharmaceuticals worth $67,365,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of the stock. Sachetta LLC increased its stake in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares in the last quarter. Adirondack Trust Co. boosted its stake in shares of Regeneron Pharmaceuticals by 2.4% in the third quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after acquiring an additional 10 shares during the last quarter. UMB Bank n.a. increased its position in shares of Regeneron Pharmaceuticals by 1.1% during the third quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after purchasing an additional 10 shares in the last quarter. Catalyst Financial Partners LLC raised its stake in Regeneron Pharmaceuticals by 3.8% in the 2nd quarter. Catalyst Financial Partners LLC now owns 326 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 12 shares during the last quarter. Finally, Trust Co. of Vermont lifted its holdings in Regeneron Pharmaceuticals by 8.3% in the 3rd quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company’s stock valued at $165,000 after purchasing an additional 12 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $731.30 on Friday. The company’s 50 day simple moving average is $849.77 and its 200-day simple moving average is $1,004.02. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a 1 year low of $728.68 and a 1 year high of $1,211.20. The company has a market capitalization of $80.36 billion, a price-to-earnings ratio of 18.10, a price-to-earnings-growth ratio of 2.32 and a beta of 0.08.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. BMO Capital Markets dropped their target price on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Citigroup began coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They set a “neutral” rating and a $895.00 price objective for the company. Bank of America reissued an “underperform” rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. Royal Bank of Canada dropped their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. Finally, Piper Sandler reduced their price objective on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,099.90.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.